Neovasc Announces Results for the Fourth Quarter and Fiscal Year 2015
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Canaccord Genuity Cuts Price Target on Neovasc (NVCN) to $9.50; Reiterates Buy
March 30, 2016 10:04 AM EDTCanaccord Genuity maintained a Buy rating on Neovasc (NASDAQ: NVCN), and cut the price target to $9.50 (from $15.00). Cannaccord continues to see NVCN as an attractive long-term asset in the potentially huge Transcatheter mitral valve replacement (TMVR) space. However, clinical and market development hurdles remain for all, and enrollment in NVCNs TIARA-1... More
Neovasc (NVCN) Outpaces Q4 Loss Views
March 29, 2016 4:40 PM EDTNeovasc (NASDAQ: NVCN) reported Q4 EPS of ($0.11), $0.04 better than the analyst estimate of ($0.15). Revenue for the quarter came in at $2.24 million versus the consensus estimate of $3.26 million.
For earnings history and earnings-related data on Neovasc (NVCN) click here.
... More